Copyright: ©Author(s) 2026.
World J Exp Med. Sep 20, 2026; 16(3): 120531
Published online Sep 20, 2026. doi: 10.5493/wjem.120531
Published online Sep 20, 2026. doi: 10.5493/wjem.120531
Table 2 Summary of regulations and limitations of markers of receptor activator of NF-kappaB/receptor activator of NF-kappaB ligand/osteoprotegerin axis
| Marker | Type | Clinical use | Variability | Limitations |
| RANKL | Regulatory | Experimental | High | Assay variability, not standardized |
| OPG | Regulatory | Experimental | Moderate | Influenced by multiple systemic factors |
| RANKL/OPG ratio | Integrated marker | Emerging | Moderate | Lack of standardized cut-offs |
| PINP[156] | Bone formation marker | Established | Low | Reflects slower changes |
| β-CTX[157] | Bone resorption marker | Established | Moderate | Diurnal variation |
- Citation: Lalotra T, Gunasekar A, Jeyaraman N, Nallakumarasamy A, Muthu S, Devanand V, Jeyaraman M. Osteoprotegerin and receptor activator of NF-kappaB ligand as biomarkers for bone resorption-related disorders. World J Exp Med 2026; 16(3): 120531
- URL: https://www.wjgnet.com/2220-315x/full/v16/i3/120531.htm
- DOI: https://dx.doi.org/10.5493/wjem.120531